BioNTech
biontech.com
Actively hiring
Vaccines
Cell & Gene Therapy
Infectious Disease Therapeutics
Oncology Therapeutics
Prescription Drugs
View 21 jobs
Follow
Overview
Technologies
Salaries
Products
People
Growth
Offices
Jobs
Financials
Overview
BioNTech is a German biotechnology company founded in Mainz in 2008 by the physician-scientists Ugur Sahin and Ozlem Tureci to develop individualised cancer immunotherapies using messenger RNA. Its mRNA platform, refined over a decade on oncology programmes, was redirected in early 2020 to produce Comirnaty with Pfizer, the first COVID-19 vaccine authorised in the West and the source of tens of billions of euros in revenue. The company has reinvested that windfall into its original mission, running a broad clinical pipeline of mRNA cancer vaccines, individualised neoantigen therapies and bispecific antibodies including the closely watched BNT327 programme.
Tech stack
Technologies named in job postings at BioNTech over the last 12 months, by layer, with the share of postings for each.
Technologies in use
35
Postings analysed
19
Stack modernity
66/100
Languages
ABAP21%
JavaScript11%
PowerShell11%
Python11%
Databases
Amazon Redshift5%
Cloud & platforms
AWS21%
Amazon ECS11%
MuleSoft11%
Power BI11%
Sign in to see how your skills match this stack
Sign In
Full BioNTech tech stack
35 technologies · by team · pay by technology · changes · similar stacks
Salary insights
Compensation ranges based on this company's open jobs
Median
$269k
Typical range
$137k – $447k
Open positions
9
9
Jobs
Junior
11.1%
Senior
22.2%
Staff
11.1%
Architect
55.6%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Junior | 1 | $137k | $137k |
| Senior | 2 | $170k | $159k – $182k |
| Staff | 1 | $318k | $318k |
| Architect | 5 | $269k | $234k – $447k |
Highest paying role
General Manager, U.S.
$447k
Normalized to USD per year
All salaries at BioNTech
By role, level and city, against the market · 9 jobs with pay
Products
Cell Therapies
The cell therapy programmes cover CAR-T and other engineered immune cell approaches to solid tumours. They complement the company's mRNA and antibody platforms.
biontech.com
BNT327
BNT327 is a bispecific antibody targeting PD-L1 and VEGF-A, partnered with Bristol Myers Squibb in a multibillion dollar deal. It is the most closely watched asset in the company's oncology pipeline.
biontech.com
FixVac
FixVac is the off-the-shelf mRNA cancer vaccine platform targeting shared tumour antigens. Programmes include melanoma and head and neck cancer candidates.
biontech.com
iNeST
iNeST is the individualised neoantigen-specific immunotherapy programme, where a vaccine is manufactured for each patient's own tumour mutations. It is the clearest expression of the company's founding thesis.
biontech.com
Comirnaty
Comirnaty is the COVID-19 messenger RNA vaccine BioNTech developed with Pfizer. It was the first such vaccine authorised in the West and remains the company's principal revenue source.
biontech.com
People
Ugur Sahin
Co-Founder & Chief Executive Officer
Ugur Sahin co-founded BioNTech in 2008 and leads it as chief executive. A physician and immunologist, he redirected the company's mRNA platform to a COVID vaccine within days of reading about the outbreak.
Ozlem Tureci
Co-Founder & Chief Medical Officer
Ozlem Tureci co-founded BioNTech and serves as its chief medical officer. She is an immunologist and physician who has worked on cancer immunotherapy with Ugur Sahin for three decades.
Christoph Huber
Co-Founder
Christoph Huber co-founded BioNTech and was a professor of haematology and oncology in Mainz. He mentored the founding scientists and shaped the company's clinical direction.
Jens Holstein
Chief Financial Officer
Jens Holstein leads BioNTech's finance organisation. He joined in 2021 after serving as chief financial officer of the pharmaceutical services group Fresenius Medical Care.
Sierk Poetting
Executive Officer
Sean Marett
Executive Officer
Ryan Richardson
Executive Officer
Annemarie Hanekamp
CEO
Ulrich Wandschneider
Director
Michael Motschmann
Director
Helmut Jeggle
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
58/100
Growing
Open positions
55
8 opened / 4 closed in 30 days
Median time-to-fill
25 days
faster than 47% of the market
ATS activity
Every ~19 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Industrial Engineering
19% ▲
Operations
14% ▲
Enterprise Apps
13% ▼
QA
7% ▲
Leadership
7% ▲
Product
6% ▲
Actively hiring for Industrial Engineering (+11 in 30 days)
Activity Timeline
Added CAPA to stack
Oct 2026
Offices
Where the company hires and what each office is for
Cities
11
Hiring now
11
Countries
4
Busiest office
Mainz
Loading the map
Headquarters
Builds here
Office with open vacancies
Tap a pin for the office
Mainz
Germany
HQ
Our corporate sustainability and responsibility
20 open roles 25 posted in 90 days 35% engineering 1000-5000 est. staff
hires for Enterprise Apps, Operations, DevOps
Nantong
China
Plant / site
11 open roles 13 posted in 90 days 27% engineering 1000-5000 est. staff
hires for Industrial Engineering, QA, Leadership
Shanghai
China
Regional office
11 open roles 12 posted in 90 days 36% engineering 1000-5000 est. staff
hires for Enterprise Apps, Operations, Industrial Engineering
Gaithersburg
United States
Regional office
4 open roles 5 posted in 90 days 50% engineering 500-1000 est. staff $226k Avg Salary
hires for Science & Research, Communications, Operations
Berkeley Heights
United States
Corporate office
3 open roles 3 posted in 90 days 200-500 est. staff $316k Avg Salary
hires for Management, Operations, Public Policy
Zhuhai
China
2 open roles 4 posted in 90 days 200-500 est. staff
hires for Leadership, Finance
Beijing
China
2 open roles 2 posted in 90 days 200-500 est. staff
hires for Public Policy
Cambridge
United States
2 open roles 2 posted in 90 days 50% engineering 200-500 est. staff $214k Avg Salary
hires for Operations, Science & Research
Munich
Germany
1 open roles 2 posted in 90 days 200-500 est. staff
hires for Administrative
Berlin
Germany
1 open roles 1 posted in 90 days 50-200 est. staff
hires for Product
Kigali
Rwanda
1 open roles 1 posted in 90 days 50-200 est. staff
hires for Operations
Jobs
Apply
≈ $109k – $247k per year (Estimated) • In office • 7+ years exp • Mainz
Apply
≈ $109k – $247k per year (Estimated) • In office • 7+ years exp • Mainz
Apply
≈ $95k – $233k per year (Estimated) • In office • Bachelor's Degree • Mainz
Apex
MuleSoft
DevOps
AWS
Apply
≈ $52k – $117k per year (Estimated) • In office • 10+ years exp • Bachelor's Degree • Nantong
Apply
≈ $56k – $136k per year (Estimated) • In office • 8+ years exp • Shanghai
Apply
≈ $73k – $123k per year (Estimated) • In office • 5+ years exp • Mainz
Python
JavaScript
PowerShell
C#
Apex
MuleSoft
Frontend
GraphQL
DevOps
Rest API
SOAP
IoT
OPC UA
Apply
≈ $75k – $127k per year (Estimated) • In office • 5+ years exp • Berlin
ServiceNow
Agile
ITIL
Apply
≈ $83k – $186k per year (Estimated) • In office • Bachelor's Degree • Mainz
SQL
Azure
AWS
Analytics
ETL/ELT
Informatica
Master Data Management
Apply
≈ $100k – $245k per year (Estimated) • In office • 8+ years exp • Master's Degree • Mainz
EU AI Act
NIST AI RMF
Machine Learning
Cybersecurity
Threat Modeling
OWASP
Apply
≈ $81k – $137k per year (Estimated) • In office • 3+ years exp • Mainz
Apply
≈ $81k – $137k per year (Estimated) • In office • 3+ years exp • Bachelor's Degree • Mainz
Apply
Financials
Total raised
$745M
Latest round
IPO
Funding rounds
3
Investors
4
Funding rounds
| Round | Announced | Amount | Valuation |
|---|---|---|---|
| IPO | 2019 | $150M | $3.4B |
| Series B | 2019 | $325M | — |
| Series A | 2018 | $270M | — |
Key Investors
Pfizer
Pfizer invested in BioNTech alongside their vaccine collaboration agreement. The partnership produced Comirnaty and shared its worldwide profits.
pfizer.com
Redmile Group
Redmile Group co-led BioNTech's Series A round. The firm specialises in healthcare and life sciences investing.
redmilegrp.com
Fidelity
Fidelity led BioNTech's Series B financing in 2019. The asset manager frequently anchors late-stage biotechnology rounds.
fidelity.com
Struengmann Family Office
The Struengmann brothers, who built and sold the generics maker Hexal, provided BioNTech's founding capital and remain its largest shareholders. Their patience funded a decade of pre-revenue research.
athos.de